Cytiva Fibro PrismA antibody purification technology

Cytiva’s Fibro PrismA antibody purification technology has been designed to support the industry’s drive for increased speed and flexibility, in order to advance the development of novel therapeutics. The first product based on the company’s protein A fibre chromatography technology, it is being used to accelerate research for customers and collaborators.

Fibro chromatography technology enables rapid cycling antibody purification. In research and process development, this means Fibro PrismA can support up to 20 times increased throughput compared with traditional resins, the company claims. In clinical and commercial manufacturing, the technology will enable efficient single-use operations, by using the full unit lifetime in a single batch.

Fibro PrismA enables ultrafast purification in research and process development, allowing researchers to accelerate the drug discovery process. Clinical-scale products are set to follow.